Irida Kastrati, Ph.D.
Affiliations: | 2009 | University of Illinois at Chicago, Chicago, IL, United States |
Area:
Pharmaceutical ChemistryGoogle:
"Irida Kastrati"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Gregory Thatcher | grad student | 2009 | University of Illinois, Chicago | |
| (Mechanisms of estrogen carcinogenesis in human breast epithelial cells.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ekyalongo RC, Flowers B, Sharma T, et al. (2023) SELENOF Controls Proliferation and Cell Death in Breast-Derived Immortalized and Cancer Cells. Cancers. 15 |
| Sharma T, Zhang Y, Zigrossi A, et al. (2023) Dimethyl fumarate inhibits ZNF217 and can be beneficial in a subset of estrogen receptor positive breast cancers. Breast Cancer Research and Treatment |
| Flowers B, Bochnacka O, Poles A, et al. (2023) Distinct Roles of SELENOF in Different Human Cancers. Biomolecules. 13 |
| Semina SE, Alejo LH, Chopra S, et al. (2022) Identification of a novel ER-NFĸB-driven stem-like cell population associated with relapse of ER+ breast tumors. Breast Cancer Research : Bcr. 24: 88 |
| Flowers B, Poles A, Kastrati I. (2022) Selenium and breast cancer - An update of clinical and epidemiological data. Archives of Biochemistry and Biophysics. 732: 109465 |
| Zigrossi A, Hong LK, Ekyalongo RC, et al. (2022) SELENOF is a new tumor suppressor in breast cancer. Oncogene. 41: 1263-1268 |
| Kastrati I, Joosten SEP, Semina SE, et al. (2020) The NFκB pathway promotes tamoxifen tolerance and disease recurrence in estrogen receptor positive breast cancers. Molecular Cancer Research : McR |
| Kastrati I, Semina S, Gordon B, et al. (2019) Insights into how phosphorylation of estrogen receptor at serine 305 modulates tamoxifen activity in breast cancer. Molecular and Cellular Endocrinology. 483: 97-101 |
| Kastrati I, Brovkovych SD, Stender JD, et al. (2018) Abstract 5242: NFĸB pathway activation is a key determinant of tamoxifen tolerance and recurrence in breast cancer Cancer Research. 78: 5242-5242 |
| Smart E, Kastrati I, Frasor J. (2018) Abstract 2158: Inhibition of NFkB restores tamoxifen responsiveness in resistant estrogen receptor positive breast cancer in a syngeneic mouse model Cancer Research. 78: 2158-2158 |